Compare CSX Corporation (CSX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs ResMed Inc. — how do they compare? CSX Corporation trades at $47.31 (market cap $87.70B), while ResMed Inc. trades at $230.57 (market cap $31.89B). The key difference: CSX Corporation is far larger — about 2.8× ResMed Inc.'s market cap, and CSX Corporation pays the higher dividend (1.18%). Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and ResMed Inc. for 51 Days on average.
| CSX | RMD | |
|---|---|---|
Market Cap | $87.70B | $31.89B |
Volume | 6,980,781 | 618,314 |
Sector | Industrials | Health |
52-Week High | $53.21 | $277.88 |
52-Week Low | $33.68 | $182.82 |
Typical Hold Time | 55 Days | 51 Days |
Enterprise Value | $105.66B | $31.24B |
Dividend Yield | 1.18% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.28, up 0.99% today, with a bullish technical signal and strong institutional interest. The railroad operator shows solid profitability with 22.2% net margins and 24.4% ROE, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analysts maintain a buy consensus with a $51 target, representing 8% upside. Recent news highlights upcoming Q3 earnings and institutional acquisitions.
CSX offers moderate upside potential with strong operational metrics offset by revenue pressures. Key opportunities include pricing power in freight rail and dividend growth, while risks involve economic sensitivity and competitive threats. The stock's premium valuation requires sustained execution to justify current levels.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
